Pernix Therapeutics (PTX) Reports Q2 Loss of $0.47/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
August 11, 2016 4:01 PM EDTNet Revenue Increased 13% Sequentially Over First Quarter 2016
Recently Completed Reorganization of Management Team and Restructuring of Sales Force and Operations
MORRISTOWN, N.J., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2016.
Second Quarter 2016 Financial and Product Highlights:
Net... More